Mesoblast (NASDAQ:MESO) Stock Rating Upgraded by Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Mesoblast (NASDAQ:MESO) to a strong-buy rating in a research report sent to investors on Tuesday morning,Zacks.com reports. Cantor Fitzgerald also issued estimates for Mesoblast’s FY2025 earnings at ($0.70) EPS.

Other analysts have also issued reports about the stock. Jefferies Financial Group lowered shares of Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. Piper Sandler restated an “overweight” rating and set a $24.00 target price (up from $15.00) on shares of Mesoblast in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Mesoblast Stock Down 7.7 %

MESO stock opened at $13.68 on Tuesday. The company’s 50 day moving average price is $17.94 and its 200 day moving average price is $12.33. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. Mesoblast has a fifty-two week low of $2.05 and a fifty-two week high of $22.00.

Hedge Funds Weigh In On Mesoblast

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MESO. Creative Planning acquired a new position in Mesoblast in the third quarter valued at approximately $147,000. XY Capital Ltd acquired a new position in Mesoblast in the third quarter valued at approximately $244,000. Jane Street Group LLC boosted its holdings in Mesoblast by 46.4% in the third quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock valued at $695,000 after purchasing an additional 26,959 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Mesoblast by 22.1% in the fourth quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock valued at $133,000 after purchasing an additional 1,213 shares in the last quarter. Finally, Ballentine Partners LLC acquired a new stake in shares of Mesoblast in the fourth quarter valued at approximately $222,000. 1.43% of the stock is owned by institutional investors and hedge funds.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.